MedTrace Logo

Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer

NCT01774266 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2013-06-03

No results posted yet for this study

Summary

In this proposal the investigators aim to develop a commercial kit to be used in primary screening and non-invasive triage for early detection of gastric cancer. This kit will be cost-effective and more accessible to the general population. In addition, the investigators would like to expand our current patent already submitted to INAPI (National Institute for Intellectual Property) and propose royalties to biomedical diagnostic companies for the use of our product at international level.

Conditions

  • Early Gastric Cancer

Sponsors & Collaborators

  • Ministerio de Salud de Chile

    collaborator UNKNOWN

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Red Salud UC

    collaborator UNKNOWN

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-12-31
Completion
2014-03-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01774266 on ClinicalTrials.gov